Physician profile
Amy E Geer
NPI 1528141553
$4,891.84
in general payments reported to CMS, 2019-2025
31 companies · $1,198 in 2025
The $1,198 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.70 · 2020: $24.60 · 2021: $360 · 2022: $938 · 2023: $1,218 · 2024: $1,128 · 2025: $1,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,543.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $444.81 | 2021-2025 | Qelbree, Qelbree |
| Abbvie INC. | $439.60 | 2021-2025 | |
| Pfizer INC. | $423.33 | 2022-2025 | |
| Dexcom, INC. | $390.91 | 2021-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $363.87 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $347.28 | 2021-2025 | Airsupra, Fasenra, Farxiga |
| Corcept Therapeutics | $343.40 | 2024-2025 | Korlym |
| Amgen INC. | $322.09 | 2023-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $294.19 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $210.55 | 2021-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $153.65 | 2022-2023 | |
| Sanofi Pasteur INC. | $141.48 | 2022-2025 | |
| Exact Sciences Corporation | $132.08 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $105.35 | 2024-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.72 | 2022-2024 | Jardiance |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $92.52 | 2021-2023 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.06 | 2022-2024 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $72.53 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $65.17 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $63.55 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $62.48 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $48.00 | 2021 | |
| Idorsia Pharmaceuticals US INC | $33.94 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $32.30 | 2022-2024 | Gardasil 9, Gardasil, Vaxneuvance |
| Abbott Laboratories | $28.22 | 2021-2022 | |
| Medtronic USA, INC. | $25.70 | 2019 | |
| Ironshore Pharmaceuticals INC. | $19.61 | 2024 | |
| Astellas Pharma US INC | $17.21 | 2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $14.64 | 2025 | Zoryve |
| Medtronic Vascular, INC. | $13.07 | 2020 | |
| Genentech USA, INC. | $11.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Geer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.